PreludeDx Validates AidaBreast Test for Personalized Radiation Therapy in Breast Cancer
Event summary
- PreludeDx published a multi-institutional validation study in Breast Cancer Research on March 12, 2026, demonstrating AidaBreast's ability to predict locoregional recurrence risk and radiation therapy benefit in early-stage invasive breast cancer.
- The study evaluated 922 hormone receptor-positive (HR+), HER2-negative patients across four centers with a median follow-up of 10 years.
- AidaBreast integrates NextGen RNA expression, multiplex protein biomarkers, and spatial biology to provide prognostic and predictive insights.
- PreludeDx positions AidaBreast alongside DCISionRT to lead personalized radiation therapy decisions in early-stage breast cancer.
The big picture
PreludeDx's validation of the AidaBreast test underscores a broader industry shift toward multi-omic approaches in cancer treatment, moving away from reliance on clinicopathologic features alone. The company is positioning itself as a leader in personalized radiation therapy decisions, building on its established DCISionRT test to cover a wider spectrum of early-stage breast cancer care.
What we're watching
- Clinical Adoption
- The pace at which AidaBreast will be integrated into clinical guidelines and treatment protocols.
- Market Differentiation
- Whether PreludeDx can sustain its leadership in personalized radiation therapy decisions with both DCISionRT and AidaBreast.
- Regulatory Approval
- The timeline for further validation studies and potential regulatory approvals to expand AidaBreast's use.
Related topics